Ó³»­´«Ã½

Kimberly Stegmaier, an institute member at the Ó³»­´«Ã½ of MIT and Harvard, professor of pediatrics at Harvard Medical School, and the Ted Williams Investigator at the Dana-Farber Cancer Institute, has pioneered the application of genomics to drug and protein target discovery for pediatric malignancies. 

Stegmaier is the vice chair for pediatric oncology research, co-director of the Pediatric Hematologic Malignancy Program, and an attending physician providing clinical care in pediatric oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital. Stegmaier serves on the Cancer Program’s scientific advisory committee at the Ó³»­´«Ã½. She is a board member of the American Association for Cancer Research (AACR) and chair of the St. Jude Children’s Research Hospital’s scientific advisory board, and served as the chair for the AACR’s Pediatric Cancer Working Group (2018-2021) and as a council member for the Society for Pediatric Research (2013-2016). 

Stegmaier is the recipient of numerous awards, such as the Joanne Levy, MD, Memorial Award for Outstanding Achievement from the American Society of Hematology; the Society for Pediatric Research Young Investigator Award; a Stand Up to Cancer (SU2C) Innovative Research Grant; an E. Mead Johnson Award for Research in Pediatrics; an NCI Outstanding Investigator R35 Award; and a St. Baldrick’s Foundation Robert J. Arceci Innovation Award. She was elected to the American Society of Clinical Investigation and the Association of American Physicians. Her deep commitment to training the next generation of researchers has been recognized with the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School and the Casty Family Achievement in Mentoring Award from the Dana-Farber Cancer Institute.

Stegmaier received her undergraduate degree from Duke University, where she graduated valedictorian, and a medical degree from Harvard Medical School. She trained in pediatrics and pediatric hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute.